BioSpace News Archive

NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it recently completed a Pre-Biologics License Application (“pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

Adipose derived stem cells are a subset of mesenchymal stem cells, derived from adipocytes which are capable of multipotential differentiation and self-renewal.

he industry analysis report is considered a valuable source of information about the global Implantable Heart Pacemaker industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11th Annual SVB Leerink Global Healthcare Conference.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.

Stealth BioTherapeutics Corp announced that on February 11, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is currently not in compliance with the minimum Market Value of Publicly Held Shares requirement based upon Nasdaq’s review of the Company’s MVPHS for the 30 consecutive business days through February 10, 2022.

FDNA, the leader for the early detection of rare genetic diseases, announced today that its breakthrough study findings were published in the esteemed peer-reviewed journal Nature Genetics, in a paper titled “GestaltMatcher facilitates rare disease matching using facial phenotype descriptors.”